Chapter 25: Biotechnology

The core process of genetic engineering involves isolating a target gene, inserting it into an appropriate vector, introducing the construct into a host cell, and identifying the resulting genetically modified organism. Restriction enzymes serve as precision molecular tools that recognize specific DNA sequences and cleave them to generate either blunt or sticky ends, which DNA ligase subsequently seals to form recombinant DNA molecules. Gene libraries, including genomic libraries containing complete DNA fragments and complementary DNA libraries synthesized from messenger RNA through reverse transcriptase, provide organized repositories of genetic material for research and application. The polymerase chain reaction amplifies target DNA sequences through repeated cycles of thermal denaturation, primer binding, and enzymatic extension, producing exponential copies sufficient for analysis and manipulation. Multiple vector systems including plasmids, bacteriophage lambda for large inserts, and cosmid hybrids facilitate the delivery of foreign DNA into host cells. In clinical medicine, biotechnology enables large-scale production of therapeutic proteins such as recombinant insulin, human growth hormone, and coagulation factor VIII, while also yielding antithrombotic agents like tissue plasminogen activator and immunomodulatory interferons for treating viral infections and malignancies. Emerging therapeutic strategies employ antisense oligonucleotides to inhibit expression of defective genes and utilize bacteriophages as carriers for targeted drug administration. Agricultural applications include the development of transgenic crops engineered for herbicide tolerance, insect resistance through bacterial toxin genes, and enhanced nutritional composition, alongside transgenic animals produced for pharmaceutical protein synthesis and improved agricultural performance, collectively addressing global food security and therapeutic supply challenges.